Benidipine

Benidipine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	C08CA15 (WHO) ;
Identifiers
	IUPAC name O5-methyl O3-[(3R)-1-(phenylmethyl)piperidin-3-yl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;
CAS Number	105979-17-7 ;
PubChem CID	656668;
ChemSpider	571013 ;
UNII	4G9T91JS7E;
ChEMBL	ChEMBL2218858 ;
Chemical and physical data
Formula	C28H31N3O6
Molar mass	505.562 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-][N+](=O)c1cccc(c1)[C@@H]4C(/C(=O)OC)=C(\N\C(=C4\C(=O)O[C@@H]3CCCN(Cc2ccccc2)C3)C)C;
	InChI InChI=1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1 ; Key:QZVNQOLPLYWLHQ-ZEQKJWHPSA-N ;
	(what is this?) (verify)

Benidipine (INN), also known as Benidipinum or benidipine hydrochloride, is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension). It is a triple L-, T-, and N-type calcium channel blocker. It is reno- and cardioprotective.

Dosing

Benidipine is dosed as 2–8 mg once daily.^[1]

Availability

Benidipine is sold as Coniel by Kyowa Hakko Kogyo.

Benidipine is only licensed for use in Japan and selected Southeast Asian countries, where it is sold as 4 mg tablets.

Mechanism

Benidipine is a calcium channel blocker.

Benidipine has additionally been found to act as an antagonist of the mineralocorticoid receptor, or as an antimineralocorticoid.^[2]

References

^ Hi-Eisai Pharmaceutical, Inc. "Coniel (benidipine) package insert (Philippines)". MIMS Philippines. CMPMedica. Retrieved 2008-03-31.
^ Luther, James M. (2014). "Is there a new dawn for selective mineralocorticoid receptor antagonism?". Current Opinion in Nephrology and Hypertension. 23 (5): 456–461. doi:10.1097/MNH.0000000000000051. ISSN 1062-4821.

[1] Hi-Eisai Pharmaceutical, Inc. "Coniel (benidipine) package insert (Philippines)". MIMS Philippines. CMPMedica. Retrieved 2008-03-31.

[Luther2014-2] Luther, James M. (2014). "Is there a new dawn for selective mineralocorticoid receptor antagonism?". Current Opinion in Nephrology and Hypertension. 23 (5): 456–461. doi:10.1097/MNH.0000000000000051. ISSN 1062-4821.

[1]

[2]